PBR28

Phase 2Small molecule

NNational Institute of Mental Health (NIMH)

PBR28 is one of 63 small molecule programs targeting AIN. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AINTerminated

NeuroinflammationRecruiting

Multiple SclerosisRecruiting

AINPreclinical

Terminated

NeuroinflammationPhase 1

Recruiting

Multiple SclerosisPhase 2

Recruiting

Competition

Competitive Landscape

145 competitors in Multiple Sclerosis

#DrugCompanyPhaseTrials

Cytoxan

BBaxter Healthcare Corporation

Phase 3

9 2

Questran

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

2 3

Versed

CConrado Roberto Hoffmann Filho

Phase 3

2 4

Zyrtec

KKenvue Brands

Phase 3

1 5

Frexalimab

Sanofi

Phase 3

2 6

Clemastine Fumarate

Novartis

Phase 3

2 7

Recombinant Zoster Vaccine

MMAXVAX Biotechnology Limited Liability Company

Phase 3

1 8

MRI Contrast-Enhancing Agents

Sanofi

Phase 3

3 9

PBR06

UUniversity Hospital, Bordeaux

Phase 3

3 10

Flomax

Sanofi

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Recruiting

Neuroinflammation

NCT04274998

Q4 2027

Phase 1/2Recruiting

Multiple Sclerosis

NCT02649985

Clinical

Trials by Indication[1]

Cysticercosis1 trial

PET Imaging of Peripheral Benzodiazepine Receptors in Patients With Neurocysticercosis Using [C-11]PBR28

Completed·NNational Institute of Mental Health (NIMH)·Phase 1·NCT00526916·18 enrolled

Multiple Sclerosis1 trial

PET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric Diseases

Recruiting·—·Phase 1/2·NCT02649985·250 enrolled

Atherosclerosis1 trial

PET Imaging of Peripheral Benzodiazepine Receptors in Patients With Carotid Atherosclerosis

Completed·NNational Institute of Mental Health (NIMH)·Phase 1·NCT00547976·5 enrolled

AIN1 trial

PET Evaluation of Brain Peripheral Benzodiazepine Receptors Using [11C]PBR28 in HIV-Seropositive Patients With (MCMD)

Terminated·NNational Institute of Mental Health (NIMH)·N/A·NCT00459693·40 enrolled

Neuroinflammation1 trial

Neuroinflammation Imaging in AD

Recruiting·UUniversity of Pennsylvania·Phase 1·NCT04274998·20 enrolled

1 more indication

Brain Injury1 trial

Translocator Protein and Inflammation After Traumatic Brain Injury

Completed·NNational Institute of Mental Health (NIMH)·Phase 1/2·NCT01547780·52 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for PBR28. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PBR28 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PBR28. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Institute of Mental Health (NIMH) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: NNational Institute of Mental Health (NIMH)

PBR28

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q4 2027

Trials by Indication[1]

Cysticercosis1 trial

Multiple Sclerosis1 trial

Atherosclerosis1 trial

AIN1 trial

Neuroinflammation1 trial

Brain Injury1 trial

References

Drug Info

Quick Facts

Related News